Effect of Sequential Eradication Therapy on Serum Osteoprotegerin Levels in Patients with Infection and Co-existing Inflammatory Bowel Disease

Overview

Journal J Int Med Res

Publisher Sage Publications

Specialty General Medicine

Date 2021 Dec 1

PMID 34851775

Citations 1

Authors

Hussam Murad

Misbahuddin Rafeeq

Mahmoud Mosli

Mamdouh Gari

Mohammed Basheikh

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the effect of sequential eradication therapy on serum osteoprotegerin levels in patients with infection and co-existing inflammatory bowel disease (IBD).

Methods: Three groups of patients were involved in this observational cross-sectional study: IBD (n = 83), infection (HP, n = 68), and infection with co-existing IBD (HP + IBD, n = 52). These groups were compared with a normal control group (NC, n = 50). Serum osteoprotegerin, serum bone alkaline phosphatase (BALP), and fecal calprotectin (FC) levels were measured.

Results: Serum osteoprotegerin levels were significantly correlated with the simple endoscopic score for Crohn's disease and Mayo score for ulcerative colitis. The receiver operating characteristic analysis of osteoprotegerin revealed high values for the area under the curve, sensitivity, and specificity. Discriminant analysis illustrated that osteoprotegerin levels significantly differentiated patients with IBD from healthy controls. Osteoprotegerin and FC levels distinguished the IBD and HP + IBD groups from the NC and HP groups.

Conclusions: Sequential eradication therapy did not affect serum osteoprotegerin levels in patients with infection and co-existing IBD. Serum osteoprotegerin elevation might be a marker for IBD development in patients with past or current infection.

Citing Articles

Impact of Eradication on Inflammatory Bowel Disease Onset and Disease Activity: To Eradicate or Not to Eradicate?.

Gravina A, Pellegrino R, Iascone V, Palladino G, Federico A, Zagari R Diseases. 2024; 12(8).

PMID: 39195178 PMC: 11353643. DOI: 10.3390/diseases12080179.

References

Matuszewska A, Nowak B, Rzeszutko M, Zduniak K, Szandruk M, Jedrzejuk D . Effects of long-term administration of pantoprazole on bone mineral density in young male rats. Pharmacol Rep. 2016; 68(5):1060-4. DOI: 10.1016/j.pharep.2016.06.012. View

Shinzaki S, Fujii T, Bamba S, Ogawa M, Kobayashi T, Oshita M . Seven days triple therapy for eradication of Helicobacter pylori does not alter the disease activity of patients with inflammatory bowel disease. Intest Res. 2018; 16(4):609-618. PMC: 6223447. DOI: 10.5217/ir.2018.00044. View

Kappelman M, Rifas-Shiman S, Kleinman K, Ollendorf D, Bousvaros A, Grand R . The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007; 5(12):1424-9. DOI: 10.1016/j.cgh.2007.07.012. View

Shih H, Hsu T, Chen C, Lin C, Kao C, Chen C . Analysis of Patients with Helicobacter pylori Infection and the Subsequent Risk of Developing Osteoporosis after Eradication Therapy: A Nationwide Population-Based Cohort Study. PLoS One. 2016; 11(9):e0162645. PMC: 5023099. DOI: 10.1371/journal.pone.0162645. View

Robinson K . Mediated Protection against Extra-Gastric Immune and Inflammatory Disorders: The Evidence and Controversies. Diseases. 2017; 3(2):34-55. PMC: 5548235. DOI: 10.3390/diseases3020034. View

KalantarHormozi M, Assadi M, Vahdat K, Asadipooya K, Ostovar A, Raissi K . Chlamydia pneumoniae and Helicobacter pylori IgG seropositivities are not predictors of osteoporosis-associated bone loss: a prospective cohort study. J Bone Miner Metab. 2015; 34(4):422-8. DOI: 10.1007/s00774-015-0688-9. View

Sylvester F, Turner D, Draghi 2nd A, Uuosoe K, McLernon R, Koproske K . Fecal osteoprotegerin may guide the introduction of second-line therapy in hospitalized children with ulcerative colitis. Inflamm Bowel Dis. 2011; 17(8):1726-30. DOI: 10.1002/ibd.21561. View

Wagtmans M, Witte A, Taylor D, Biemond I, Veenendaal R, Verspaget H . Low seroprevalence of Helicobacter pylori antibodies in historical sera of patients with Crohn's disease. Scand J Gastroenterol. 1997; 32(7):712-8. DOI: 10.3109/00365529708996523. View

Kakehasi A, Mendes C, Coelho L, Castro L, Barbosa A . The presence of Helicobacter pylori in postmenopausal women is not a factor to the decrease of bone mineral density. Arq Gastroenterol. 2007; 44(3):266-70. DOI: 10.1590/s0004-28032007000300016. View

10.

Lundgren A, Suri-Payer E, Enarsson K, Svennerholm A, Lundin B . Helicobacter pylori-specific CD4+ CD25high regulatory T cells suppress memory T-cell responses to H. pylori in infected individuals. Infect Immun. 2003; 71(4):1755-62. PMC: 152046. DOI: 10.1128/IAI.71.4.1755-1762.2003. View

11.

Algaba A, Linares P, Encarnacion Fernandez-Contreras M, Ordonez A, Trapaga J, Guerra I . Relationship between levels of angiogenic and lymphangiogenic factors and the endoscopic, histological and clinical activity, and acute-phase reactants in patients with inflammatory bowel disease. J Crohns Colitis. 2013; 7(11):e569-79. DOI: 10.1016/j.crohns.2013.04.005. View

12.

Schoppet M, Henser S, Ruppert V, Stubig T, Al-Fakhri N, Maisch B . Osteoprotegerin expression in dendritic cells increases with maturation and is NF-kappaB-dependent. J Cell Biochem. 2006; 100(6):1430-9. DOI: 10.1002/jcb.21129. View

13.

Asaoka D, Nagahara A, Hojo M, Sasaki H, Shimada Y, Yoshizawa T . The Relationship between H. pylori Infection and Osteoporosis in Japan. Gastroenterol Res Pract. 2014; 2014:340765. PMC: 4082917. DOI: 10.1155/2014/340765. View

14.

Daperno M, DHaens G, Van Assche G, Baert F, Bulois P, Maunoury V . Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc. 2004; 60(4):505-12. DOI: 10.1016/s0016-5107(04)01878-4. View

15.

Kim T, Lee H, Min Y, Min B, Lee J, Rhee P . Cohort study of Helicobacter pylori infection and the risk of incident osteoporosis in women. J Gastroenterol Hepatol. 2020; 36(3):657-663. DOI: 10.1111/jgh.15181. View

16.

Franchimont N, Reenaers C, Lambert C, Belaiche J, Bours V, Malaise M . Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients. Clin Exp Immunol. 2004; 138(3):491-8. PMC: 1809233. DOI: 10.1111/j.1365-2249.2004.02643.x. View

17.

Aubin J, Bonnelye E . Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos Int. 2001; 11(11):905-13. DOI: 10.1007/s001980070028. View

18.

Fotouk-Kiai M, Hoseini S, Meftah N, Ghadimi R, Bijani A, Noreddini H . Relationship between Helicobacter pylori infection (HP) and bone mineral density (BMD) in elderly people. Caspian J Intern Med. 2015; 6(2):62-6. PMC: 4478452. View

19.

Rosania R, von Arnim U, Link A, Rajilic-Stojanovic M, Franck C, Canbay A . Helicobacter pylori eradication therapy is not associated with the onset of inflammatory bowel diseases. A case-control study. J Gastrointestin Liver Dis. 2018; 27(2):119-125. DOI: 10.15403/jgld.2014.1121.272.hpy. View

20.

Xiang Z, Chen Y, Ye Y, Ma K, Chen S, Zheng L . Helicobacter pylori and Crohn's disease: a retrospective single-center study from China. World J Gastroenterol. 2013; 19(28):4576-81. PMC: 3725384. DOI: 10.3748/wjg.v19.i28.4576. View